i3 Health

11/29/2025

EMBARK update: ADT + enzalutamide shows a dramatic OS benefit (>40% relative reduction) in high‑risk BCR after local therapy. What it means for practice, who benefits most (by PSA doubling time), and how to manage toxicities.

Read more here: https://bit.ly/3M5yIco

11/28/2025

Black Friday deal for oncology nurses! 🛍️

Advance your oncology nursing expertise and earn ILNA points for your ONCC certification renewal—at half the price. For a limited time, enjoy 50% off all i3 Health premium activities with code FALL50 at checkout.

- Evidence-based oncology education
- ILNA-approved activities
- Flexible, on-demand learning

Don’t miss this Black Friday savings event–Use code FALL50 and upgrade your learning for 50% off! Start now at i3Health.com.

11/27/2025

Happy Thanksgiving from i3 Health! We’re especially grateful for the healthcare professionals and teams who dedicate themselves to improving patient outcomes every day.

Wishing you a safe and restful holiday. 🦃

11/26/2025

Your Update: Here’s what’s new this week from i3 Health!

New i3 Health Activity: Virtual Tumor Board Challenge - Navigating Treatment Selection and Sequencing in Metastatic Prostate Cancer: https://bit.ly/48ielQp

Evolving Standards in Prostate Cancer: Lessons From ESMO 2025 With Stephen Freedland, MD, and Murilo Luz, MD: https://bit.ly/48pDNDR

Sevabertinib Granted Accelerated Approval for Non-Squamous NSCLC: https://bit.ly/48hlvVc

11/26/2025

"Treatment decisions should consider prognostic risk, comorbidities, prior treatments, resources required, and patient preference"

Start this insightful activity today: https://bit.ly/46JfAHL

11/25/2025

Advanced NSCLC is evolving. HER2 alterations are targets, with multiple agents in study and T‑DXd approved for pretreated, HER2‑mutated disease.

Watch Module 2 on YouTube for HER2‑based management: https://www.youtube.com/watch?v=nuqnM_Ug7yE&t=238s

Claim your credit here: https://bit.ly/49qGllhView and download the slide deck here: https://www.slideshare.net/slideshow/what-s-new-with-her2-charting-new-p...

11/25/2025

🚀 Jump-start your experience on Friday with i3 Health! Join us for an engaging panel discussion on optimizing hemophilia outcomes.

Seats are limited. Register Now➜ https://bit.ly/3KWIbly

11/24/2025

With oncogenic drivers and targeted therapies, comprehensive molecular assessment is now a cornerstone of NSCLC care. HER2 alterations (mutations, amplifications, overexpression) are emerging targets, but their heterogeneity complicates testing and treatment selection.

Watch Module 1 on YouTube for actionable insights and testing recommendations for HER2 in NSCLC: https://www.youtube.com/watch?v=aJj0bXnlnSg

Claim your CME/NCPD credit here: https://bit.ly/3HgJgDuComplete Module 2 here: https://youtu.be/3zWERGHtUu80:00 - Introduction00:46 - Prioritizing biomarker-...

11/23/2025

November is Neuroendocrine Cancer Awareness Month. Neuroendocrine tumors are often slow-growing and frequently misdiagnosed, leading to delayed detection.

11/22/2025

How can genetic counseling and testing transform cancer care for your patients?

Explore pathways to precision medicine and claim free CME/NCPD/CE:

Join Dr. Filipa Lynce and Catherine Skefos as they discuss strategies for integrating genetic testing into clinical practice: https://bit.ly/3Votk5YView and ...

11/21/2025

Meet our Faculty Friday feature: Danielle Hutchings, MD, Assistant Professor of Pathology and Laboratory Medicine at Cedars‑Sinai Medical Center.

She specializes in surgical pathology with expertise in GI, pancreatobiliary, and liver pathology and has authored/coauthored numerous publications in GI pathology.

Explore the activity: https://bit.ly/3IhmFXL

11/20/2025

November 20 is World Pancreatic Cancer Day. We honor those affected by pancreatic cancer and stand with the clinicians, researchers, and caregivers dedicated to improving outcomes. 💜